68 results about "Mixed Cellular Population" patented technology

Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.

A unitary apparatus for isolating cells from adipose tissue including a lipid separation processor with a dispersing head equipped with a plurality of ports and a digestion chamber for dissociation of the constituent cells disposed in adipose tissue. The lipid separating apparatus is useful for the separation of lipids and adipocytes from a mixed cell population. A cell seeding chamber may be attached to the cell isolation apparatus. The components of the apparatus may be packaged in modular kit form.

The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for the production of TRC populations with greater tissue repair and anti-inflammatory capabilities. Embodiments of the present invention include a post-culture process for cultured cells that preferably includes the steps of: a wash process for removing unwanted residual culture components, a volume reduction process, and a harvesting process to remove cultured cells. Preferably, all these steps are performed within a aseptically closed cell culture chamber by implementing a separation method that minimizes mechanical disruption of the cells and is simple to automate. The harvested cells may then be concentrated to a final volume for the intended use. In such embodiments, the final composition is a substantially purified and concentrated cell mixture suspended in a physiologic solution suitable for immediate use in humans without further washing, volume reduction, or processing. Embodiments are also applicable to harvesting (and/or washing) particles within a liquid or solution within a chamber.

A method for identifying a sub-population within a mixed population of cells is disclosed. The method involves contacting the mixed population of cells with at least one unique binding agent, wherein the at least one unique binding agent is designed to bind to a target molecule present in the sub-population, and wherein the at least one unique binding agent is attached to an epitope specific barcode that represents the identity of the target molecule. The method further involves sequentially attaching two or more assayable polymer subunits to the epitope specific barcode to create unique cell origination barcodes that represent the identities of individual cells to which the at least one unique binding agent has bound; and decoding the epitope specific barcode and cell origination barcodes, thereby identifying the sub-population within the mixed population of cells.

An apparatus for sorting cells from a mixed population of cells using surface acoustic waves is described. Methods for separating cancer cells from a mixed population of cells are provided. Methods for separating cells or particles having different size, density and/or compressibility properties are also provided.

Methods and systems are provided for massively parallel genetic analysis of single cells in emulsions or droplets. A biological sample is divided into subsamples of single cells or cell supbopulations, and a fusion complex is formed by molecular linkage and amplification techniques. Methods, apparatuses, and systems are provided for high-throughput, massively parallel analysis of the subsamples. These methods integrate molecular, algorithmic, and engineering approaches. They have broad and useful application in a number of biological and medical fields, including immunology, noninvasive prenatal diagnosis, and noninvasive cancer diagnosis.

The invention relates to a bispecific antibody or antibody mixture, and more specifically relates to the bispecific antibody or the antibody mixture having a common light chain, and a preparation method of the bispecific antibody or the antibody mixture. The invention also relates to nucleic acid molecules for coding the bispecific antibody or the antibody mixture, a recombinant vector containing the nucleic acid molecules and recombinant cells, and a detection and quantification method for the bispecific antibody or the antibody mixture. The bispecific antibody or the antibody mixture is prepared by a common light chain technology, the preparation method is simple and controllable, mismatching of the light chains in the bispecific antibody can be avoided, the antibody mixture can be expressed in same host cell, difficulty for culturing the mixed cell groups is reduced, and the amplification production is easily achieved.

The present invention comprises an implantable device that provides artificial tissues for repair, augmentation and reconstructive surgery which have mechanical properties comparable to the natural tissues that they supplement or replace. Such devices can be produced by a tissue engineering method comprising seeding a polymer matrix with a first cell type and a second cell type and culturing the seeded matrix under conditions suitable for cell growth or maintenance, whereby a tissue comprising a mixed cell population containing both the first and second cell types is produced. The tissue produced by this method contains a mixed population in which the two cell types are intimately associated without apparent stratification and has mechanical properties which are intermediate between similarly produced tissues containing either one of the two cell types. This invention is particularly useful in forming implantable structural members.

One of the major hurdles of cellular therapies for the treatment of liver failure is the low availability of functional human hepatocytes. Although embryonic stem (ES) cells represent a potential cell source for therapy, current methods for differentiation result in mixed cell populations or low yields of the cells of interest. The present invention provides for a rapid, direct differentiation method that yields a homogeneous population of endoderm-like cells with 95% purity. In one embodiment, mouse ES cells cultured on top of collagen-sandwiched hepatocytes differentiate and proliferate into a uniform and homogeneous cell population of endoderm-like cells. The endoderm-like cell population was positive for Foxa2, Sox17 and AFP, and could further differentiate into hepatocyte-like cells that demonstrate hepatic morphology, functionality, and gene and protein expression. Incorporating the hepatocyte-like cells into a bioartificial liver device to treat fulminant hepatic failure improved animal survival, thereby underscoring the therapeutic potential of these cells.

The invention belongs to the field of biological and medical detection, and relates to a system for separating CTCs (circulating tumor cells) in a blood sample from a mixed cell group in high purity. The separation system for the CTCs comprises a sample preparation module, a sample injection module, a first micro-fluidic chip, a release module and a collection module, wherein the sample preparation module is used for processing blood into a detection sample; the sample injection module is used for injecting the detection sample into the first micro-fluidic chip; the first micro-fluidic chip is used for extracting the CTCs in the detection sample; the release module is used for separating the CTCs from the first micro-fluidic chip and obtaining a collection sample; and the collection module is used for collecting the collection sample. According to the technical scheme, compared with the prior art, the separation system for the CTCs is simple, easy to implement, lower in cost, simple to operate and high in automation degree.

The present invention provides: a method for producing mixed cells comprising cardiomyocytes, endothelial cells and mural cells from induced pluripotent stem cells, the method comprising (a) a step of producing cardiomyocytes from induced pluripotent stem cells and (b) a step of culturing the cardiomyocytes in the presence of VEGF; and a therapeutic agent for heart diseases, comprising the mixed cells produced by the method.

The present invention is directed to a method of separating oligodendrocyte cells or progenitor cells thereof from a mixed population of cells. It comprises selecting a promoter which functions only in the oligodendrocyte cells or progenitor cells thereof, introducing a nucleic acid molecule encoding a fluorescent protein under control of that promoter into the mixed population cells, allowing the oligodendrocyte cells or progenitor cells thereof to express the fluorescent protein, and separating the fluorescent cells from the mixed population cells, where the separated cells are the oligodendrocyte cells or progenitor cells thereof. The invention also relates to the isolated and enriched human oligodendrocyte cells or progenitor cells thereof.

The invention belongs to the field of biological and medical detection and relates to equipment, a system and a method for separating CTCs (circulating tumor cells) in a blood sample from mixed cell groups with high purity. The equipment and system for separating the CTCs comprise, but not limited, a control module, a sample injection module, a separation module and a collection module, wherein the control module is used for setting equipment operation parameters including diluents volume, reaction time, sample injection speed, cleaning parameter and the like; the sample injection module adopts a multi-way valve module and a peristaltic pump module and is used for automatically diluting detected samples and starting multi-channel synchronous separation of the samples; the separation module comprises a magnet module and a separator module, the magnet module is used for separating and adsorbing magnetic particle immunolabeled blood leukocytes, and the separator module is used for enriching and separating CTCs from multiple cell groups; the collection module is used for collecting a separated CTC suspension. The invention provides the equipment and the system for separating the CTCs as well as the method for separating and identifying the CTCs.

The present invention is directed to a method of isolating an enriched or purified population of motor neurons from a population of embryonic stem cells. This method involves providing a population of embryonic stem cells and selecting a promoter or enhancer which functions only in the motor neurons selected. A nucleic acid molecule encoding a marker protein under control of the promoter or enhancer is introduced into the induced population of embryonic stem cells. The motor neurons are allowed to express the marker protein and, the cells expressed in the marker protein are separated from the population of embryonic stem cells. The population of embryonic stem cells can be induced to produce a mixed population of cells comprising motor neurons before or after a nucleic acid molecule encoding the marker protein under control of the promoter enhancer is introduced into the population of embryonic stem cells. As a result, an enriched or purified population of motor neurons is isolated.

The present invention provides methods for treating critical limb ischemia (CLI), including increasing wound healing, decreasing wound size, increasing survival-free amputation, preventing amputation, preventing or delaying de novo gangrene, increasing survival probability, and preventing or delaying death, in subjects who prevent a vascular occlusion that cannot be resolved by using a standard method of revascularization, i.e. a subject with “no-option” CLI. Methods of the invention include administering to a subject with no-option CLI an isolated cell composition for tissue repair comprising a mixed population of cells of hematopoietic, mesenchymal and endothelial lineage, wherein the viability of said cells is at least 80% and the composition contains: a) about 5-75% viable CD90⁺ cells with the remaining cells in said composition being CD45⁺; b) less than 2 μg/ml of bovine serum albumin; c) less than 1 μg/ml of a enzymatically active harvest reagent; and d) substantially free of mycoplasma, endotoxin, and microbial contamination.

Methods for detecting the presence or absence of, and for quantifying, one set of cells in a mixed cell population of at least two sets of cells especially Rh positive cells in a mixed population with Rh negative cells, as is found in a fetal maternal hemorrhage (FMH).

The magnetic particles coated with anti-D antibodies are reacted with the Rh positive fetal cells in Rh negative maternal blood followed by a specific separation and quantifying technique.

Gravitational forces or magnetic forces are used to move reacted magnetic particles to isolate, distinguish and quantify cells differentiated by antigenic composition.

Rh positive cell volume is correlated to the volume of the original blood sample as an indication of the number of doses of RhIG needed to be administered to the mother to prevent subsequent Rh immunization.

The invention relates to a method and a related kit for detecting c-MET/CEP7 gene status based on rare cells, wherein the method comprises the following steps: 1. acquiring a blood sample or a body fluid sample, wherein the sample includes a mixed cell population of circulating tumor cells or other rare cells and white blood cells; 2. diluting the sample by virtue of a buffer solution, removing plasma and recovering CTC or other rare cells; 3. cracking by virtue of a red blood cell lysis buffer, removing red blood cells and recovering CTC or other rare cells; 4. recovering cells with magnetic particles coated with related anti-human leucocyte antigens and antibodies, uniformly mixing and breeding, and fully combining so as to form a magnetic particle-white blood cell mixture; 5. isolating the magnetic particle-white blood cell mixture from other cells so as to obtain a mixed cell population containing CTC or other rare cells and a few of white blood cells; and 6. by virtue of a method combining immunofluorescence cytochemistry and fluorescence in-situ hybridization, determining the status of c-MET/CEP7, and simultaneously identifying CTC or other rare cells.

A method of selecting retinal pigmented epithelial (RPE) cells from a mixed population of cells is disclosed. The method comprises:

• • (a) analyzing the cells of the mixed population of cells for at least one of the following parameters:
  • (i) cells which autofluorescence above a predetermined threshold;
  • (ii) cells which express CD81 above a predetermined threshold; and
  • (iii) cells which scatter light perpendicular to a laser beam above a predetermined threshold; and
  • (b) selecting cells which are positive for at least one of the parameters, thereby sorting RPE cells from a mixed population of cells.

A method and an apparatus for rapid cell separation without using density gradient and antibody but using a column packed with resin particles. The interactions between cell surfaces and resin particles resulting in the different retention time of different cells in the column contribute to the separation of the specific cells from the mixed cell population. Therefore, no antibodies and specific chemical reagents are used in cell separation maintain the physiological status of separated cells. This invention can also apply to clinical use for fast and massive separation of blood sub-population, for the remove of leukemia cells from normal leucocytes in vivo or in vitro, and particularly for drug screening through the interaction between drugs and specific and non-specific cells.

The present invention relates to a method for treating a tumor that contains fibrin. The method comprises utilizing an energy from an energy source to destroy at least a portion of (i) a fibrin contained in the tumor or (ii) fibrin surrounded tumor. The energy may also cause necrosis of tumor cells that are adjacent to the fibrin. The method further include the use of a tumor-targeting monoclonal antibody conjugated to a toxin which is administered to the subject. The present invention also relates to a method for removing and killing fibrin-associated tumor cells from a mixed cell population, which method includes the step of delivering an energy from an energy source to the fibrin-associated tumor cells and killing the tumor cells with a tumor-targeting monoclonal antibody conjugated to a toxin.